Recent Patents on Anti-Cancer Drug Discovery

Scope & Guideline

Empowering the Fight Against Cancer through Science

Introduction

Delve into the academic richness of Recent Patents on Anti-Cancer Drug Discovery with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1574-8928
PublisherBENTHAM SCIENCE PUBL LTD
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2006 to 2024
AbbreviationRECENT PAT ANTI-CANC / Recent Patents Anti-Canc. Drug Discov.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES

Aims and Scopes

The journal 'Recent Patents on Anti-Cancer Drug Discovery' focuses on the latest advancements in cancer treatment through the analysis and review of recent patents, highlighting innovative therapeutic strategies and drug development processes.
  1. Patent Analysis in Cancer Therapeutics:
    The journal emphasizes the examination of patents related to novel anti-cancer agents, their mechanisms of action, and potential therapeutic applications, providing insights into the evolving landscape of cancer treatment.
  2. Molecular Mechanisms and Biomarkers:
    Research articles often explore the molecular underpinnings of cancer, including the identification of biomarkers that predict response to therapies and the mechanisms driving tumor progression.
  3. Emerging Therapeutic Strategies:
    The journal highlights cutting-edge therapeutic modalities such as immunotherapy, targeted therapies, and nanotechnology, offering a platform for discussing their applications and efficacy in clinical settings.
  4. Bioinformatics and Computational Approaches:
    Many studies utilize bioinformatics tools to analyze genetic and molecular data, enabling the identification of novel targets for drug development and personalized medicine approaches.
  5. Natural Products and Traditional Medicine:
    The journal also explores the potential of natural compounds and traditional remedies in cancer therapy, reviewing their pharmacological properties and patent status.
Recent publications in the journal indicate several emerging themes and trends in cancer research, reflecting the dynamic nature of the field and the ongoing quest for innovative therapeutic solutions.
  1. Immunotherapy and Checkpoint Inhibition:
    There is a growing emphasis on immunotherapeutic strategies, particularly those targeting immune checkpoints, as researchers investigate their potential to enhance anti-tumor responses and improve patient outcomes.
  2. Targeted Therapy and Precision Medicine:
    The focus on targeted therapies continues to rise, with studies identifying specific molecular targets for drug development, aligning with the broader trend towards precision medicine in oncology.
  3. Nanotechnology in Drug Delivery:
    Research exploring nanotechnology applications in cancer treatment is expanding, highlighting novel drug delivery systems that enhance the efficacy and reduce the side effects of anti-cancer therapies.
  4. Role of the Tumor Microenvironment:
    An increased interest in the tumor microenvironment and its influence on cancer progression and treatment response is evident, with studies examining how this niche can be targeted therapeutically.
  5. Bioinformatics and Machine Learning Applications:
    The integration of bioinformatics and machine learning approaches in cancer research is emerging, facilitating the analysis of large datasets to identify new therapeutic targets and predict treatment outcomes.

Declining or Waning

While the journal maintains a strong focus on various aspects of cancer drug discovery, certain themes have shown a decline in prominence, reflecting shifts in research priorities and advancements in technology.
  1. Conventional Chemotherapy Agents:
    There is a noticeable decrease in publications focusing solely on traditional chemotherapy agents, as the field shifts towards more targeted and personalized therapies that address the unique characteristics of tumors.
  2. General Reviews of Cancer Treatments:
    Broad reviews of existing cancer treatments are less frequent, with a move towards more specific analyses of novel compounds or targeted therapies, indicating a preference for detailed and focused studies.
  3. In vitro Studies without Clinical Relevance:
    The journal appears to be moving away from in vitro studies that do not translate into clinical applications, favoring research that demonstrates clear pathways to clinical utility and patient outcomes.

Similar Journals

Oncologie

Elevating oncology research to new heights.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

Biomarker Research

Connecting global minds to elevate biomarker science.
Publisher: BMCISSN: Frequency: 1 issue/year

Biomarker Research is a leading open access journal published by BMC, dedicated to advancing the field of biomarker discovery and clinical application. Since its inception in 2013, this journal has become a crucial resource for researchers and professionals in biochemistry, clinical biochemistry, and molecular medicine, achieving a prestigious Q1 ranking in each category in 2023. With an E-ISSN of 2050-7771, it maintains a strong reputation for disseminating high-quality research and innovative findings that contribute to the understanding of disease mechanisms and the development of novel diagnostics and therapeutics. The journal is accessible to a global audience, ensuring that vital research is freely available to promote collaboration and accelerate scientific progress. Operating out of the United Kingdom, Biomarker Research plays a significant role in addressing some of the most pressing challenges in medical research, making it an essential resource for academics, clinicians, and industry professionals alike.

Journal of Natural Medicines

Transforming Research into Practice in Natural Medicines
Publisher: SPRINGER JAPAN KKISSN: 1340-3443Frequency: 4 issues/year

Journal of Natural Medicines, published by SPRINGER JAPAN KK, is a leading academic journal that plays a pivotal role in the advancement of research in the fields of Complementary and Alternative Medicine, Drug Discovery, Molecular Medicine, Organic Chemistry, and Pharmaceutical Science. Established in 1994 and set to continue until 2024, this journal serves as a vital conduit for the dissemination of groundbreaking research and innovative ideas that bridge traditional medicinal knowledge and modern scientific inquiry. With its impressive ranking in Scopus—ranking #12 out of 105 in Complementary and Alternative Medicine and holding a Q1 category quartile for 2023—it stands as a reputable source for high-quality, peer-reviewed articles. The journal's commitment to excellence is further underscored by its inclusion in the Springer network, providing researchers, professionals, and students with valuable insights and the latest developments in natural medicines. Although this journal operates under a subscription model, its profound impact on these interdisciplinary fields makes it an essential resource for anyone engaged in the study or practice of natural medicinal therapies.

ONCOLOGY RESEARCH

Advancing the Frontiers of Cancer Research
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Fostering collaboration for groundbreaking cancer discoveries.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Discovery Medicine

Advancing medical knowledge through innovative research.
Publisher: DISCOVERY MEDICINEISSN: 1539-6509Frequency: 6 issues/year

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

BioImpacts

Elevating global discourse in medical and pharmaceutical advancements.
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5652Frequency: 4 issues/year

BioImpacts, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, is a prominent platform dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Medicine, and Pharmaceutical Science. Established in 2011, this Open Access journal ensures that vital research findings are freely accessible to the global academic community. With an impressive presence in the Scopus database, BioImpacts currently holds a Q2 quartile ranking in its respective categories, reflecting its contribution to scientific discourse and its importance as a critical resource for researchers and practitioners alike. The journal's dynamic scope encompasses a wide range of topics, highlighting innovative research that addresses contemporary challenges in health and disease. Operating out of Tabriz, Iran, BioImpacts is committed to fostering interdisciplinary collaboration and knowledge dissemination through their dedicated publication efforts, which span from 2011 to 2024. Researchers, professionals, and students are encouraged to explore the rich content and cutting-edge studies presented in this journal, making it an indispensable resource in the scientific community.

Biomolecules & Therapeutics

Transforming Discoveries into Therapeutic Solutions
Publisher: KOREAN SOC APPLIED PHARMACOLOGYISSN: 1976-9148Frequency: 4 issues/year

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

Trends in Cancer

Elevating Knowledge in Cancer Science and Medicine
Publisher: CELL PRESSISSN: 2405-8025Frequency: 12 issues/year

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

CANCER RESEARCH

Pioneering insights into cancer biology and treatment.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 0008-5472Frequency: 24 issues/year

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.